Join Growin Stock Community!

Edesa biotech, inc.EDSA.US Overview

US StockHealthcare
(No presentation for EDSA)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

EDSA AI Insights

EDSA Overall Performance

EDSA AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

EDSA Recent Performance

-

Edesa biotech, inc.

0.05%

Avg of Sector

-0.31%

S&P500

EDSA PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

EDSA Key Information

EDSA Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

EDSA Profile

Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.

Price of EDSA

EDSA FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

EDSA Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.94
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
120477.93
PB Ratio
2.78
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.94
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
120477.93
PB Ratio
2.78
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is EDSA's latest earnings report released?

    The most recent financial report for Edesa biotech, inc. (EDSA) covers the period of 2026Q1 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating EDSA's short-term business performance and financial health. For the latest updates on EDSA's earnings releases, visit this page regularly.

  • How much cash does EDSA have?

    At the end of the period, Edesa biotech, inc. (EDSA) held Total Cash and Cash Equivalents of 12.05M, accounting for 0.82 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is EDSA's EPS continuing to grow?

    According to the past four quarterly reports, Edesa biotech, inc. (EDSA)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.28. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of EDSA?

    Edesa biotech, inc. (EDSA)'s Free Cash Flow (FCF) for the period is -2.09M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 37.58% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of EDSA?

    The latest valuation data shows Edesa biotech, inc. (EDSA) has a Price-To-Earnings (PE) ratio of -1.09 and a Price/Earnings-To-Growth (PEG) ratio of 0.1. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.